

Supplemental Data

**Loss-of-Function Variants in *PPP1R12A*: From Isolated
Sex Reversal to Holoprosencephaly Spectrum
and Urogenital Malformations**

Joel J. Hughes, Ebba Alkhunaizi, Paul Kruszka, Louise C. Pyle, Dorothy K. Grange, Seth I. Berger, Katelyn K. Payne, Diane Masser-Frye, Tommy Hu, Michelle R. Christie, Nancy J. Clegg, Joshua L. Everson, Ariel F. Martinez, Laurence E. Walsh, Emma Bedoukian, Marilyn C. Jones, Catharine Jean Harris, Korbinian M. Riedhammer, Daniela Choukair, Patricia Y. Fechner, Meilan M. Rutter, Sophia B. Hufnagel, Maian Roifman, Gad B. Kletter, Emmanuele Delot, Eric Vilain, Robert J. Lipinski, Chad M. Vezina, Maximilian Muenke, and David Chitayat

1 Supplemental Note: Case Reports

2

3 Individual 1: She was born at term to a 19-year-old mother by Cesarean delivery and weighed 3.23 kg
4 (50th centile). The pregnancy was complicated by maternal hypertension, pre-eclampsia, diabetes, and
5 exposure to alcohol and marijuana at approximately 8 weeks gestation. She had syntelencephaly/middle
6 interhemispheric variant (MIHV) of HPE, polymicrogyria, and Chiari I malformation identified on brain
7 MRI. Other medical problems included intellectual disability, attention deficit hyperactivity disorder
8 (ADHD), and seizures. Sanger sequencing of the four most common genes associated with HPE, *SHH*
9 (MIM: 600725), *ZIC2* (MIM: 603073), *SIX3* (MIM: 603714), and *TGIF* (MIM: 602630), failed to
10 identify any detectable pathogenic variants. Trio exome sequencing revealed a heterozygous *de novo*
11 variant in *PPP1R12A*, NM_002480.3:c.2033_2034del p.(Ser678*), which was confirmed by Sanger
12 sequencing.

13 Individual 2: She was a 6-year-old female with semilobar HPE and agenesis of the corpus callosum
14 identified on MRI. Other medical problems included myoclonus, intellectual disability, and syndactyly of
15 the toes. Sanger sequencing of *SHH*, *SIX3*, *ZIC2*, and *TGIF* failed to identify detectable pathogenic
16 variants. Trio exome sequencing revealed a heterozygous *de novo* variant in *PPP1R12A*,
17 NM_002480.3:c.1415C>G p.(Ser472*), which was confirmed by Sanger sequencing.

18 Individual 3: Prenatally, he had a fetal ultrasound and MRI which demonstrated agenesis of the corpus
19 callosum and colpocephaly as well as pyelectasis and intrauterine growth restriction. Chromosome
20 analysis of amniocytes showed 46,XY Normal male. A Cesarean delivery occurred at 36 2/7 weeks for
21 breech presentation and oligohydramnios. Significant findings on newborn evaluation included low birth
22 weight of 2.04 kg (3-10th centile), decreased subcutaneous fat, mild facial asymmetry, ulnar drift at the
23 wrist and fisting, upper back kyphosis, and grade 1 hydronephrosis with renal asymmetry detected by
24 ultrasound. Findings at age 5.5 years were grossly unchanged apart from additional behavioral issues
25 including ADHD and defiance. A chromosome microarray analysis (CMA) was arr(1-22)normal. Trio

26 exome sequencing through GeneDx revealed a heterozygous *de novo* splice site variant in *PPP1R12A*,
27 NM_002480.3: c.793-1G>A.

28 Individual 4: Prenatally, an 11-week antenatal ultrasound showed fetal acrania with exencephaly,
29 hypertelorism, flattened facial profile with non-visualization of the nasal bone, omphalocele, echogenic
30 bowel, and non-visualization of the lumbosacral spine. Fetal growth was normal. The parents were of
31 Chinese descent, non-consanguineous and with an unremarkable family history. The pregnancy was
32 interrupted and limited pathological assessment of the fetus and placenta at 12 weeks gestation revealed
33 the presence of a partial cranial vault with scant white-grey tissue and spinal column. Chorionic villus and
34 fetal neural, renal, gastrointestinal, and cardiac tissues were histologically examined and unremarkable.
35 Maternal serum folate and vitamin B12 levels were within normal range. CMA on products of conception
36 was arr(1-22,X)x2 normal female. *UPD11* testing and *CDKN1C* sequencing obtained due to the presence
37 of an omphalocele on ultrasound showed no abnormalities. Trio exome sequencing identified a
38 heterozygous *de novo* frameshift variant in *PPP1R12A*, NM_002480.3:c.223_224delAC
39 p.(Thr75Cysfs*8).

40 Individual 5: He was a 3-year-old male with ambiguous genitalia at birth. Physical exam revealed
41 micropenis, chordee, scrotal hypospadias, bilateral cryptorchidism, and a uterus on ultrasound. No other
42 birth defects were reported. Additionally, serum anti-Müllerian hormone levels were below normal range.
43 Karyotype was 46,XY Normal male. Developmentally, he was reported appropriate for age and had an
44 unremarkable head CT scan. Trio exome sequencing by GeneDx identified a *de novo* heterozygous
45 frameshift variant in *PPP1R12A* NM_002480.3: c.2739_2740delCT p.(Leu914Argfs*14).

46 Individual 6: He was a 6-year-old male found on fetal ultrasound, at 19 weeks of gestation, to have an
47 encephalocele at the posterior parietal region and colpocephaly. The pregnancy was complicated by
48 chronic maternal hypertension, type II diabetes mellitus controlled with insulin, and intrauterine growth
49 restriction. At birth, he was noted to have thrombocytopenia requiring platelet transfusion. He had
50 ventriculoperitoneal shunt insertion for hydrocephalus and encephalocele repair shortly after birth.
51 Postnatal MRI revealed dysgenesis of the corpus callosum, absent septum pellucidum, Chiari

52 malformation, cortical dysplasia/polymicrogyria and grey matter heterotopia. Neurological examination
53 was notable for global developmental delay, intellectual disability, autistic features, appendicular
54 hypotonia with foot pronation requiring supra malleolar orthosis (SMO) braces bilaterally, and an
55 unsteady gait. He sat at 1 year, walked at 3 years, and continued to have difficulties with expressive
56 language with limited speech. He had minor dysmorphic facial features including short upslanting
57 palpebral fissures, low-set ears, and micrognathia. Other significant features included short stature, patent
58 ductus arteriosus, and ophthalmologic abnormalities including strabismus, astigmatism, hyperopia, and
59 alternating esotropia. The genitourinary abnormalities included glandular hypospadias and chordee which
60 required surgical correction. Karyotype was 46,XY Normal male and trio exome sequencing by GeneDx
61 identified a heterozygous nonsense *de novo* variant in *PPP1R12A* NM_002480.3:c.1510C>T
62 p.(Arg504*).

63 Individual 7: He was a 7-year-old male with genitourinary malformations including hypospadias,
64 cryptorchidism, and a uterus. The prenatal and early medical history is unknown, as he was adopted out.
65 Karyotype was 46,XY Normal male. He had generalized developmental delay, seizures and brain MRI
66 showed microcephaly and leukomalacia along with opacified left tympanic cavity and mastoid air cells.
67 Facial dysmorphism was noted including long face, large prominent ears, ptosis, and a small pointed
68 nose. Other abnormalities included, 5th finger clinodactyly, and blind shallow rectal cleft. Further
69 investigation revealed delayed bone age, bilateral rod and cone dysfunction with decreased vision, and
70 latent nystagmus. Singleton exome sequencing by GeneDx revealed a heterozygous nonsense variant in
71 *PPP1R12A*, NM_002480.3:c.2573G>A p.(Trp858*).

72 Individual 8: She was a 45-year-old female with typical female external genitalia and a 46,XY Normal
73 male karyotype. Pelvic ultrasound identified a small uterus didelphys. She had a history of a bilateral
74 gonadectomy in childhood; however, the pathologist did not specify ovarian or testicular tissue on report.
75 She had primary amenorrhea and was over 6 feet tall. *SRY* and *NR5A1* gene sequencing were
76 unremarkable. There were no reported neurological issues, developmental delay, or other malformations.

77 Singleton exome sequencing performed at GeneDx identified a heterozygous frameshift in *PPP1R12A*
78 NM_002480.3:c.2073dupA p.(Ser692Ilefs*2).

79 Individual 9: She was a 9-month-old phenotypic female with a 46,XY Normal male karyotype, and had
80 external genitalia notable for clitoral hypertrophy (0.5 cm in diameter), urogenital sinus (UGS), vaginal
81 opening and posterior fusion of the labia majora. No uterus was identified on pelvic ultrasound. Prenatal
82 history was unremarkable with spontaneous vaginal delivery at 39 weeks. Biochemical workup was not
83 consistent with congenital adrenal hyperplasia. Neuroimaging was not indicated at that time. Trio exome
84 sequencing performed via a German health care project for rare diseases revealed a heterozygous *de novo*
85 nonsense variant in *PPP1R12A* NM_002480.3:c.2698C>T p.(Arg900*).

86 Individual 10: He was a 2-year-old phenotypic male with 46,XY Normal male karyotype, evaluated by
87 clinical genetics due to grade 2 hypospadias and cryptorchidism. He was born premature at 27 weeks. A
88 Fallopian tube without mention of an attached gonad was identified during surgical repair of a right
89 inguinal hernia. Abdominal ultrasound showed a uterus. Physical exam was notable for short stature,
90 macrocephaly, triangular face, long palpebral fissures, ptosis, small mouth and wide nasal tip. He had
91 global developmental delay and brain MRI was normal. A CMA was normal. Trio exome sequencing by
92 GeneDx revealed a likely pathogenic heterozygous maternally inherited variant in *SCN8A*,
93 NM_01491.3:c.2424dupT p.(Pro809Serfs*13) which was identified in a clinically unaffected sib, as well
94 as a heterozygous *de novo* variant in *PPP1R12A*, NM_002480.3:c.960dupA p.(Glu321Argfs*6).

95 Individual 11: She was a adult female with 46,XY gonadal dysgenesis, alopecia totalis, obesity and
96 acanthosis nigricans. Diagnostic laparoscopy at age 6 identified two streak gonads (abdominal on the
97 right and inguinal on the left) which were resected, with rudimentary Fallopian tubes, a vaginal opening,
98 and no uterus. She has had normal development and brain MRI was normal. At age 30, she is doing well
99 on hormone replacement therapy. Trio research genome sequencing identified a heterozygous *de novo*
100 variant in *PPP1R12A*, NM_002480.3:c.1189delA p.(Thr397Hisfs*42) which was confirmed by Sanger
101 sequencing.

102 Individual 12: She was evaluated by genetics due to discordance between the chromosome sex (46,XY)
103 on cell free non-invasive prenatal testing and the phenotypic sex as identified on fetal ultrasound showing
104 a female external genitalia. Postnatally, she was noted to have jejunal and ileal atresia. Surgery revealed
105 an aberrant mesenteric blood supply, normal-appearing ovaries with Fallopian tubes and a uterus. CMA
106 was arr(1-22)x2,(X,Y)x1 normal male. An ultrasound at 1 year showed normal kidneys and confirmed the
107 presence of a uterus, but did not identify gonads, suggesting gonadal degeneration. Examination at age 2
108 showed a clitoris, posterior labial fusion, increased labial rugation and pigmentation, and mild
109 gynecomastia. Her growth parameters were normal. She had strabismus, bilateral epicanthus inversus,
110 right esotropia, abnormal auricles, bilateral 5th digit clinodactyly, and spoon-shaped toenails. She had
111 developmental delay and autism spectrum disorder. Brain MRI has not been done. Luteinizing hormone
112 and FSH was within normal range, and anti-müllerian hormone and testosterone was lower than normal
113 range for a male with a 46,XY karyotype. Research genome sequencing identified a heterozygous *de novo*
114 variant in *PPP1R12A*, NM_002480.3:c.681dupT (p.Lys228Ter) which was confirmed by Sanger
115 sequencing.

116

117 **Supplemental Material and Methods**

118

119 **Brain: mouse *in situ* hybridization.** Genes that regulate forebrain patterning and play a role in
120 HPE pathogenesis are expected to be expressed in the prosencephalic neural folds that give rise
121 to the forebrain during primary neurulation.¹ Therefore, we conducted *in situ* hybridization (ISH)
122 on mouse embryos at gestational day (GD) 8.25. This stage is representative of early neurulation
123 and within the critical period for development of HPE.^{2,3} Studies were conducted in strict
124 accordance with the recommendations in the *Guide for the Care and Use of Laboratory Animals*
125 of the National Institutes of Health. The protocol was approved by the University of Wisconsin-
126 Madison School of Veterinary Medicine Institutional Animal Care and Use Committee (protocol

127 number G005396). CD-1 mice (*Mus musculus*) were purchased from Charles River and
128 C57BL/6J mice from The Jackson Laboratory. Timed-pregnancies were established as
129 previously described.⁴ Embryos were dissected at GD8.25 and fixed overnight in 4%
130 paraformaldehyde. *In situ* hybridization (ISH) was conducted on whole C57BL/6J embryos or 50
131 μm sections cut from CD-1 embryos with a vibrating microtome in the transverse plane along the
132 anterior-posterior axis. ISH was conducted as previously described.⁵

133

134 **Urogenital: mouse and human immunostaining.** Human lower urinary tracts were obtained
135 from the Joint MRC / Wellcome (MR/R006237/1) Human Developmental Biology Resource
136 (www.hdbr.org) under an approved University of Wisconsin-Madison IRB protocol (2016-
137 0449). C57BL/6J mouse lower urinary tracts were obtained under a University of Wisconsin-
138 Madison approved ACUC protocol (protocol number G005396). Tissues were embedded in
139 paraffin and stained with antibodies against PPP1R12A (Thermo Scientific PA579857, 1:250),
140 PPP1R12B (Sigma HPA024171, 1:250), CDH1 (BD Transduction Labs 610181, 1:250) and with
141 DAPI (nuclei) using an established method.⁶ Mouse results are representative of three
142 independent mice per group and human results are representative of one per group.

143

144 **DNA Sequence and Analysis Methods**

145

146 National Institutes of Health: DNA samples from study participants underwent exome
147 sequencing at the National Intramural Sequencing Center (NISC) as previously described.⁷ The
148 mean read depth for each sample was 79.8. Copy number variation (CNV) prediction from
149 exome data was done using the XHMM (eXome-Hidden Markov Model) caller.⁸ We used

150 GATK to generate the depth of coverage statistics required for XHMM from the BAM files of
151 our HPE cohort and a control set. GATK output was then run through the XHMM pipeline,
152 generating a VCF file containing each predicted CNV. We then annotated each CNV for genes
153 contained and cytogenetic region using Annovar. All probands were first searched for four
154 common genes known to cause HPE: *SHH* (MIM: 600725) on 7q36, *ZIC2* (MIM: 603073) on
155 13q32, *SIX3* (MIM: 603714) on 2p21, and *TGIF* (MIM: 602630) on 18p11.3 using Sanger
156 sequencing as recommended.⁹ With the goal of new gene discovery, minimizing false positives,
157 and sacrificing sensitivity, the discovery cohort was filtered with stringent criteria including *de*
158 *novo* inheritance in genes intolerant of variation,¹⁰ variant absence in the ExAC database,¹⁰ and
159 Combined Annotation-Dependent Depletion (CADD) scores above 20.¹¹ Variants that met these
160 criteria were considered deleterious. A total of 101 trios affected by holoprosencephaly (proband,
161 father, and mother) were sequenced.

162

163 Technical University of Munich: DNA was extracted from peripheral blood using the Gentra
164 Puregene Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Trio
165 exome sequencing (ES) was performed using a Sure Select Human All Exon 60 Mb V6 Kit
166 (Agilent) and a NovaSeq 6000 (Illumina) as previously described.¹² Mitochondrial DNA was
167 derived from off-target exome reads as previously described.¹³ Reads were aligned to the human
168 reference genome (UCSC Genome Browser build hg19) using Burrows-Wheeler Aligner
169 (v.0.7.5a). Detection of single-nucleotide variants and small insertions and deletions (indels) was
170 performed with SAMtools (version 0.1.19). ExomeDepth was used for the detection of copy
171 number variations (CNVs).¹⁴ For the analysis of *de novo*, autosomal dominant and mitochondrial
172 variants, only variants with a minor allele frequency (MAF) of less than 0.1% in the in-house

173 database of the Helmholtz center Munich containing over 18,000 exomes were considered. For the
174 analysis of autosomal recessive and X-linked variants (homozygous, hemizygous or compound
175 heterozygous) only variants with a MAF of less than 1.0% were considered.

176
177 Children's National Hospital: A cohort of 300 samples, belonging to 94 families with a variety of
178 syndromic or isolated DSD conditions was sequenced. Whole genome sequencing at an average
179 30x coverage was performed on a HiSeqX instrument at the Baylor facility under the Gabriella
180 Miller Kids First Initiative XO1 mechanism (<https://commonfund.nih.gov/kidsfirst/x01projects>).
181 Targeted search for exonic variants in *PPP1R12A* analysis was performed using both the Genoox
182 platform (<https://www.genoox.com/>) and the Broad Institute's *Seqr* software
183 (<https://www.seqr.broadinstitute.org/>).

184
185 GeneDx: Limited availability of detailed commercial practices regarding exome processing and
186 analysis. Test info sheet for XomeDx accessible through their public website for review
187 (<https://www.genedx.com/>).

188

189 **Supplemental References**

190

- 191 1. Geng, X., and Oliver, G. (2009). Pathogenesis of holoprosencephaly. *J Clin Invest* 119, 1403-
192 1413.
- 193 2. Heyne, G.W., Melberg, C.G., Doroodchi, P., Parins, K.F., Kietzman, H.W., Everson, J.L.,
194 Ansen-Wilson, L.J., and Lipinski, R.J. (2015). Definition of critical periods for Hedgehog

195 pathway antagonist-induced holoprosencephaly, cleft lip, and cleft palate. PLoS One 10,
196 e0120517.

197 3. Heyne, G.W., Everson, J.L., Ansen-Wilson, L.J., Melberg, C.G., Fink, D.M., Parins, K.F.,
198 Doroodchi, P., Ulschmid, C.M., and Lipinski, R.J. (2016). Gli2 gene-environment interactions
199 contribute to the etiological complexity of holoprosencephaly: evidence from a mouse model.
200 Dis Model Mech 9, 1307-1315.

201 4. Heyne, G.W., Plisch, E.H., Melberg, C.G., Sandgren, E.P., Peter, J.A., and Lipinski, R.J.
202 (2015). A Simple and Reliable Method for Early Pregnancy Detection in Inbred Mice. J Am
203 Assoc Lab Anim Sci 54, 368-371.

204 5. Everson, J.L., Fink, D.M., Yoon, J.W., Leslie, E.J., Kietzman, H.W., Ansen-Wilson, L.J.,
205 Chung, H.M., Walterhouse, D.O., Marazita, M.L., and Lipinski, R.J. (2017). Sonic hedgehog
206 regulation of Foxf2 promotes cranial neural crest mesenchyme proliferation and is disrupted in
207 cleft lip morphogenesis. Development 144, 2082-2091.

208 6. Abler, L.L., Keil, K.P., Mehta, V., Joshi, P.S., Schmitz, C.T., and Vezina, C.M. (2011). A
209 high-resolution molecular atlas of the fetal mouse lower urogenital tract. Dev Dyn 240, 2364-
210 2377.

211 7. Kruszka, P., Uwineza, A., Mutesa, L., Martinez, A.F., Abe, Y., Zackai, E.H., Ganetzky, R.,
212 Chung, B., Stevenson, R.E., Adelstein, R.S., et al. (2015). Limb body wall complex, amniotic
213 band sequence, or new syndrome caused by mutation in IQ Motif containing K (IQCK)? Mol
214 Genet Genomic Med 3, 424-432.

215 8. Fromer, M., Moran, J.L., Chambert, K., Banks, E., Bergen, S.E., Ruderfer, D.M., Handsaker,
216 R.E., McCarroll, S.A., O'Donovan, M.C., Owen, M.J., et al. (2012). Discovery and statistical

217 genotyping of copy-number variation from whole-exome sequencing depth. *Am J Hum Genet*
218 91, 597-607.

219 9. Kruszka, P., Martinez, A.F., and Muenke, M. (2018). Molecular testing in holoprosencephaly.
220 *Am J Med Genet C Semin Med Genet* 178, 187-193.

221 10. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-
222 Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al. (2016). Analysis of protein-coding
223 genetic variation in 60,706 humans. *Nature* 536, 285-291.

224 11. Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., and Shendure, J. (2014). A
225 general framework for estimating the relative pathogenicity of human genetic variants. *Nat*
226 *Genet* 46, 310-315.

227 12. Kremer, L.S., Bader, D.M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., Haack, T.B.,
228 Graf, E., Schwarzmayr, T., Terrile, C., et al. (2017). Genetic diagnosis of Mendelian disorders
229 via RNA sequencing. *Nat Commun* 8, 15824.

230 13. Griffin, H.R., Pyle, A., Blakely, E.L., Alston, C.L., Duff, J., Hudson, G., Horvath, R.,
231 Wilson, I.J., Santibanez-Koref, M., Taylor, R.W., et al. (2014). Accurate mitochondrial DNA
232 sequencing using off-target reads provides a single test to identify pathogenic point mutations.
233 *Genet Med* 16, 962-971.

234 14. Plagnol, V., Curtis, J., Epstein, M., Mok, K.Y., Stebbings, E., Grigoriadou, S., Wood, N.W.,
235 Hambleton, S., Burns, S.O., Thrasher, A.J., et al. (2012). A robust model for read count data in
236 exome sequencing experiments and implications for copy number variant calling.
237 *Bioinformatics* 28, 2747-2754.

238